Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago.
Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround
Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Why Tandem Diabetes Care Stock Took It on the Chin Tuesday
Flat revenue growth might be in store for the company in a very crucial market.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
TNDM Stock Likely to Gain From Innovation Amid Competition
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
Why Tandem Diabetes Care Stock Thrashed the Market Today
It earned a regulatory nod in one of the largest markets in the world. Approval was granted for a system to deliver an ultra-rapid insulin product developed by Eli Lilly.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
